Bml Capital Management, LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1616824) · Explore on the interactive board
Bml Capital Management, LLC disclosed 15 US equity positions worth $175.1m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 7, 2026). Its largest position is ACRS at 36.2% of the reported book, followed by AVIR, ENGN. The top ten holdings are 93.8% of the book, and the portfolio behaves like about 5 equal-weight positions. Versus the prior filing it opened 1 new position, added to 4, reduced 3 and exited 1. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Bml Capital Management, LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 1 new, 4 added, 3 reduced, 1 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 36.2% | $63.3m | 11,975,000 | -16% | reduced |
| 2 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 18.5% | $32.3m | 6,952,330 | -2% | reduced |
| 3 | ENGN ENGENE THERAPEUTICS INC | 6.6% | $11.5m | 6,669,908 | – | new | |
| 4 | KHC KRAFT HEINZ CO | Consumer Defensive | 6.3% | $11.0m | 465,000 | 272% | added |
| 5 | OM OUTSET MED INC | 6.2% | $10.9m | 2,519,701 | 32% | added | |
| 6 | KMX CARMAX INC | Consumer Cyclical | 5.2% | $9.1m | 172,500 | 11% | added |
| 7 | TLYS TILLYS INC | Consumer Cyclical | 5.2% | $9.0m | 2,150,000 | 0% | held |
| 8 | PMVP PMV PHARMACEUTICALS INC | Healthcare | 4.1% | $7.1m | 5,330,000 | 0% | held |
| 9 | TIL INSTIL BIO INC | 2.8% | $5.0m | 645,600 | 0% | held | |
| 10 | TGT TARGET CORP | Consumer Defensive | 2.8% | $4.9m | 37,500 | 0% | held |
| 11 | ORMP ORAMED PHARMACEUTICALS INC | 2.4% | $4.2m | 866,269 | -73% | reduced | |
| 12 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.4% | $2.4m | 154,961 | 0% | held |
| 13 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 1.0% | $1.8m | 1,546,137 | 0% | held |
| 14 | CNTB CONNECT BIOPHARMA HLDGS LTD | 0.8% | $1.4m | 573,287 | 40% | added | |
| 15 | IMA IMAGENEBIO INC | 0.7% | $1.2m | 200,730 | 0% | held |
What did Bml Capital Management, LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| 2KZ0 KEZAR LIFE SCIENCES INC | 100.0% | $5.3m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 61.1% |
| Consumer Cyclical | 10.4% |
| Consumer Defensive | 9.1% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Bml Capital Management, LLC's portfolio?
Across every quarter Bml Capital Management, LLC has filed, its median largest position is 35.3% of the book and its median top-ten weight is 94.0%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 1.0 completed holding spells, the median lasted 1.0 quarters; 15.0 positions are still open and their final length is unknown.